We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

The company achieved a 45% revenue growth in Q4 2024, driven by strong performance of new products like Mounjaro and Zepbound. Eli Lilly and Co (NYSE:LLY) advanced its pipeline with positive Phase ...

Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana. Read More on LLY: Eli Lilly ...

Eli Lilly may appeal to investors for its pill version of tirzepatide—likely on the horizon in 2026—as well as for its oncology products. Indeed, the company's pipeline is impressive overall.

Eli Lilly and Company discovers, develops ... It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant ...